Provided herein are substituted 1,2,3,4-tetrahydro-1,1-biphenyl compounds and methods of making same.

Provided herein are substituted 1,2,3,4-tetrahydro-1,1-biphenyl compounds and methods of making same.

A catalyst includes a carrier, and a metal obtained by reducing a metal ion supported on the carrier 1) in a supercritical state or 2) in a polar organic solvent, wherein the carrier is an inorganic porous body having a hierarchical porous structure. By employing the catalyst, it is possible to exhibit better catalytic activity than a conventional catalyst. Heat generation and spontaneous ignition are prevented because no organic porous body is used.

A catalyst includes a carrier, and a metal obtained by reducing a metal ion supported on the carrier 1) in a supercritical state or 2) in a polar organic solvent, wherein the carrier is an inorganic porous body having a hierarchical porous structure. By employing the catalyst, it is possible to exhibit better catalytic activity than a conventional catalyst. Heat generation and spontaneous ignition are prevented because no organic porous body is used.

A catalyst includes a carrier, and a metal obtained by reducing a metal ion supported on the carrier 1) in a supercritical state or 2) in a polar organic solvent, wherein the carrier is an inorganic porous body having a hierarchical porous structure. By employing the catalyst, it is possible to exhibit better catalytic activity than a conventional catalyst. Heat generation and spontaneous ignition are prevented because no organic porous body is used.

A method for treating cancer can include administering a therapeutically effective amount of a compound of formula (Ia): ##STR00001##
or pharmaceutically acceptable salts or solvates thereof, wherein R.sup.1a, R.sup.1b, R.sup.1c, R.sup.1d, R.sup.2, and R.sup.3 are as defined, and A----B is selected from CHCH, CHCH(CH.sub.2).sub.pCH.sub.2, or CH.sub.2CH.sub.2(CH.sub.2)pCH.sub.2, and where p is 1 or 2.

A method for treating cancer can include administering a therapeutically effective amount of a compound of formula (Ia): ##STR00001##
or pharmaceutically acceptable salts or solvates thereof, wherein R.sup.1a, R.sup.1b, R.sup.1c, R.sup.1d, R.sup.2, and R.sup.3 are as defined, and A----B is selected from CHCH, CHCH(CH.sub.2).sub.pCH.sub.2, or CH.sub.2CH.sub.2(CH.sub.2)pCH.sub.2, and where p is 1 or 2.

Provided are synthesis processes and intermediates for preparing cannabinoids and analogs.

Provided are synthesis processes and intermediates for preparing cannabinoids and analogs.

Provided are synthesis processes and intermediates for preparing cannabinoids and analogs.